For your patients with Lennox-Gastaut Syndrome (LGS)
BANZEL® offers powerful add-on efficacy for multiple seizure types
See the proven efficacy data of BANZEL® and how it stacks up as an adjunctive treatment across 10 different seizure types associated with LGS
An adjunctive therapy for seizures associated with LGS:
↓32.7%
median reduction in total seizure frequency per
28 days relative to baseline in the BANZEL®
(rufinamide) group (n=74) vs 11.7% for placebo
(n=64) (P<0.002)1,2
Primary Endpoint
↓42.5%
median reduction in tonic-atonic seizure (drop
attack) frequency per 28 days relative to
baseline in the BANZEL® group (n=73) vs a 1.4%
increase for placebo (n=60) (P<0.0001)1,2
Primary Endpoint
21.9%
of patients experienced a ≥75% reduction in
tonic-atonic seizure (drop attack) frequency from
baseline at 28 days in the BANZEL® group (n=73)
vs 3.3% for placebo (n=60) (P<0.007)3
Secondary Endpoint
Study Design
- A 12-week, randomized, double-blind, multicenter, placebo-controlled, parallel-group trial to assess the effectiveness of BANZEL® to reduce inadequately controlled seizures associated with LGS in patients (N=138, intent to treat) being treated with 1 to 3 concomitant stable-dose anti-epileptic drugs (AEDs)1-3
- Baseline characteristics of BANZEL® study participants were similar between study groups (BANZEL® vs placebo)1:
- Gender (62.2% male vs 62.5% male), median age (13 years vs 10.5 years), median duration of LGS (8 years vs 8 years), and median weight (36 kg vs 34 kg)
- Trial population age was 4 to 30 years at randomization
The safety of BANZEL® has been evaluated in adult and pediatric patients
References: 1. Glauser et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950-1958. 2. BANZEL® (rufinamide) prescribing information, Eisai Inc. 3. Data on file, Eisai Inc.